Business · Companies · 2 hrs ago
Iambic Therapeutics raises $150 million in Nasdaq IPO
Iambic Therapeutics raised $150 million in an initial public offering on Oct.
14, 2026.
The US startup uses artificial intelligence to help discover and develop medicines.
It sold nearly 9.4 million shares at $16 each and was due to begin trading on Nasdaq under the ticker IAM the next day.
Since its launch in 2019, Iambic has raised $462 million from private investors.
Its lead candidate, an oral drug for HER2-positive cancers, is being tested in people; early Phase 1 results showed anti-tumor activity and an encouraging safety profile in patients whose cancers had not responded to several earlier treatments.
Iambic says a larger trial that could support approval may start as soon as 2027, while two other cancer drug candidates could enter testing next year.
The IPO gives Iambic more funding to advance its medicines, but AI-based drug companies have faced difficulties after going public, and claims about what the technology can deliver have drawn scrutiny.
Iambic Therapeutics raised $150 million in an initial public offering on Oct. 14, 2026.
The AI-focused drug discovery company sold close to 9.4 million shares at $16 each.
Its shares were set to begin trading on Nasdaq the following day under the ticker symbol IAM.
Iambic has raised $462 million from private investors since its launch in 2019.
Its lead drug candidate is an oral cancer treatment that has shown early clinical anti-tumor activity, according to the company.
- Who
- Iambic Therapeutics, a startup using artificial intelligence to discover medicines.
- What
- It raised $150 million in an initial public offering.
- When
- Oct. 14, 2026.
- Where
- Nasdaq; the company was set to begin trading there under the ticker IAM.
- Why
- To fund its work developing medicines, including advancing its first drug into early human testing.
This story does not have two clearly opposing sides.
Iambic launched.
The company raised $150 million in its IPO, selling close to 9.4 million shares at $16 each.
Iambic was set to begin trading publicly on Nasdaq under the ticker IAM.
- IPO proceeds
- $150 million
- Shares sold
- Close to 9.4 million
- IPO price
- $16 per share
- Trading ticker
- IAM
- Private funding since launch
- $462 million
- Lead drug candidate
- IAM1363, being developed for HER2-positive solid tumors
What people are saying
pursuing a fundamental shift in the biopharmaceutical industry
disrupt legacy drug discovery paradigms
multi-billion dollar market opportunities